News
Recap: Ovid Therapeutics Q4 Earnings
8 Mar 24
Earnings
Ovid Therapeutics Q4 2023 GAAP EPS $(0.220) Misses $(0.100) Estimate, Sales $141.562K Beat $56.500K Estimate
8 Mar 24
Earnings, Earnings Beats, Earnings Misses, News
Ovid Therapeutics Filed U.S. Patent Application #20240009160: Use Of (S)-3-amino-4-(Difluoromethylenyl)cyclopent-1-ene-1-carboxylic Acid In The Treatment Of Cancer
11 Jan 24
News